Basic Information
| LncRNA/CircRNA Name | LL22NC03-N64E9.1 |
| Synonyms | NA |
| Region | GRCh38_22:15796959-15798346 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot, RIP, ChIP etc. |
| Sample | CRC tissues, cell lines (DLD-1, Lovo, HT-29, SW480, SW620, and HCT116) |
| Expression Pattern | up-regulated |
| Function Description | LL22NC03-N64E9.1 is upregulated in human CRC tissues and is positively correlated with larger tumor size and advanced TNM stage. LL22NC03-N64E9.1 oncogenic function may partially depend on repressing KLF2. LL22NC03-N64E9.1 confered an oncogenic function in human CRC and may serve as a candidate prognostic biomarker and target for new therapies in this deadly disease. silenced LL22NC03-N64E9.1 expression could suppress colorectal cancer cells tumor growth in vivo. |
| Pubmed ID | 28938648 |
| Year | 2017 |
| Title | A novel lncRNA, LL22NC03-N64E9.1, represses KLF2 transcription through binding with EZH2 in colorectal cancer. |
External Links
| Links for LL22NC03-N64E9.1 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |